103 related articles for article (PubMed ID: 2318446)
1. Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancer.
Hansen F; Malthe I; Krog H
Gynecol Oncol; 1990 Mar; 36(3):369-70. PubMed ID: 2318446
[TBL] [Abstract][Full Text] [Related]
2. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
Rose PG; Blessing JA; Mayer AR; Homesley HD
J Clin Oncol; 1998 Feb; 16(2):405-10. PubMed ID: 9469322
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of VP-16-213 in advanced ovarian carcinoma.
Hillcoat BL; Campbell JJ; Pepperell R; Quinn MA; Bishop JF; Day A
Gynecol Oncol; 1985 Oct; 22(2):162-6. PubMed ID: 4054715
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer. Results of the South-East European Oncology Group (SEEOG) Study.
Eckhardt S; Hernádi Z; Thurzó L; Telekes A; Sopkova B; Mechl Z; Pawlicki M; Kerpel-Fronius S
Oncology; 1990; 47(4):289-95. PubMed ID: 2195412
[TBL] [Abstract][Full Text] [Related]
5. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
[TBL] [Abstract][Full Text] [Related]
6. Chronic daily administration of oral etoposide--a phase I trial.
Hainsworth JD; Johnson DH; Frazier SR; Greco FA
J Clin Oncol; 1989 Mar; 7(3):396-401. PubMed ID: 2918334
[TBL] [Abstract][Full Text] [Related]
7. [Early phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical or ovarian cancer. ETP 21 Study Group--Cervical-Ovarian Cancer Group].
Noda K; Tanaka K; Ozaki M; Hirabayasi K; Hasegawa K; Nishiya I; Yakushiji M; Izumi R; Tomoda Y; Ogita Y; Sugimori H; Yamabe T; Kudo R; Yajima A; Terashima Y; Fujii S; Suzuoki Y; Okada H; Kono I; Ochiai K; Yamamoto T; Ikeda M; Umesaki N; Saito T; Niitani H
Gan To Kagaku Ryoho; 1998 Nov; 25(13):2061-8. PubMed ID: 9838908
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
Lund B; Hansen OP; Hansen HH; Hansen M
Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma.
De Lena M; Lorusso V; Romito S
Cancer Treat Rep; 1986 Jul; 70(7):893-5. PubMed ID: 3719581
[TBL] [Abstract][Full Text] [Related]
10. Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors.
Cooper MA; Einhorn LH
J Clin Oncol; 1995 May; 13(5):1167-9. PubMed ID: 7738621
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
Rose PG; Rodriguez M; Walker J; Greer B; Fusco N; McGuire W
Gynecol Oncol; 2002 Apr; 85(1):136-9. PubMed ID: 11925133
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer.
Hwang JH; Yoo HJ; Lim MC; Seo SS; Park SY; Kang S
Anticancer Drugs; 2012 Mar; 23(3):321-5. PubMed ID: 22156765
[TBL] [Abstract][Full Text] [Related]
13. [A study of combined chemotherapy with MMC, ADM, CDDP, etoposide (VP-16), 5'DFUR (MAC-VD therapy) in advanced cancer and local relapse of the stomach].
Yasutake K; Imamura Y; Yoshimura Y; Oya M; Matsushita K; Tokisue M; Ohno S; Masuda T
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):397-401. PubMed ID: 2138004
[TBL] [Abstract][Full Text] [Related]
14. Vincristine with high-dose etoposide in advanced breast cancer: a phase II trial of the Piedmont Oncology Association.
Thomas GW; Muss HB; Jackson DV; McCulloch J; Ramseur W; McFarland J; Hoen H; Pavy M; Heath R
Cancer Chemother Pharmacol; 1994; 35(2):165-8. PubMed ID: 7987995
[TBL] [Abstract][Full Text] [Related]
15. Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.
Gronlund B; Engelholm SA; Horvath G; Mäenpää J; Ridderheim M
Cancer; 2005 Apr; 103(7):1388-96. PubMed ID: 15719439
[TBL] [Abstract][Full Text] [Related]
16. [A phase II study of oral VP-16 in primary lung cancer].
Matsui Y; Ohshima S; Kado M; Nakayama M; Shimokata K; Sakai S; Ito F; Chikata E; Hara K; Kanda T
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1801-7. PubMed ID: 2994576
[TBL] [Abstract][Full Text] [Related]
17. [A phase II study of intravenous VP-16-213 in small cell and non-small cell carcinoma of the lung].
Konno K; Nagahama F; Nakai Y; Nakabayashi T; Hiraga Y; Takebe K; Tamura M; Oizumi K; Sato M; Ito T
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):931-7. PubMed ID: 3008671
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel, carboplatin, and oral etoposide as initial treatment for advanced ovarian carcinoma: a Minnie Pearl Cancer Research Network phase II trial.
Hainsworth JD; Kalman L; Castine M; Sylvester L; Greco FA
Gynecol Oncol; 2005 Apr; 97(1):200-5. PubMed ID: 15790459
[TBL] [Abstract][Full Text] [Related]
19. A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer.
Splinter T; Kok T; Kho S; Lameris H; ten Kate F; Dalesio O; Dolman B; Palmen F; Bouvy J; Burghouts J
Semin Oncol; 1986 Sep; 13(3 Suppl 3):97-103. PubMed ID: 3020707
[TBL] [Abstract][Full Text] [Related]
20. First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.
Athanassiou AE; Bafaloukos D; Pectasides D; Dimitriadis M; Varthalitis I; Barbounis V
Br J Cancer; 1989 Nov; 60(5):755-8. PubMed ID: 2803952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
